Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Marketing Status Prescription; Discontinued
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 68071-3093; 54288-140; 65862-538; 63415-0056; 68382-989; 17478-106; 70518-0932; 69097-282; 43063-457; 0143-9722; 61919-704; 80425-0076; 63187-384; 63323-355; 68083-415; 55111-279; 55150-156; 71335-0965; 67296-0897; 0904-6351; 70518-0968; 0781-5792; 67296-0972; 55154-5897; 42571-168; 51407-429; 50090-4572; 71335-0593; 63629-8070; 53002-3350; 68071-4512; 63187-514; 69097-289; 52343-120; 13668-083; 52343-121; 67296-1641; 55150-157; 0781-5791; 36000-295; 80425-0007; 68071-4926; 55111-281; 71205-234; 50090-1228; 65977-0039; 50090-2001; 67296-0975; 53002-2350; 55154-5898; 36000-294; 44567-436; 0143-9720; 44567-437; 63187-003; 68071-2074; 0143-9316; 68071-1860; 63187-833; 69097-287; 53002-2582; 53104-7550; 55111-280; 43063-637; 36000-048; 50383-286; 68071-4874; 68071-3166; 68180-241; 43063-459; 58118-1022; 68071-4726; 25021-132; 71335-0327; 71335-0133; 68071-4875; 67296-0977; 42708-122; 43063-638; 51407-430; 68180-242; 0527-1948; 0143-9721; 63187-925; 53069-0600; 68083-414; 71335-0391; 67296-1393; 50090-4797; 63187-004; 71335-0794; 68083-395; 50090-2498; 68071-3236; 71335-0434; 65841-692; 67296-1351; 71335-0380; 70934-094; 72578-098; 68071-4738; 43235-0007; 65841-691; 36000-296; 68071-3218; 63629-7681; 63187-438; 67296-0985; 31722-723; 65862-488; 65862-536; 54348-611; 50090-3214; 67296-1535; 72578-099; 0143-9317; 66721-200; 70518-2249; 61919-440; 43063-796; 53002-1350; 70934-050; 68788-6938; 0409-0528; 33342-023; 0781-5790; 67296-0744; 72578-100; 65841-693; 17478-107; 51407-428; 68083-416; 50090-4573; 49587-102; 68071-4900; 31722-722; 13668-084; 63629-4843; 61919-426; 65862-537; 70518-0453; 71205-002; 13668-082; 67296-1400; 68788-6816; 71335-0525; 80425-0009; 50090-4928; 70934-392; 67296-1546; 70771-1079; 52343-119; 45865-758; 36000-046; 44567-435; 55700-729; 0904-6353; 61919-987; 71335-1277; 31722-721; 68083-394; 68180-240; 67296-1325; 80425-0008; 72189-338; 36000-045; 67296-0998; 70518-2145; 71205-058; 72789-085; 80425-0077; 33342-022; 53002-1391; 0904-6352; 55525-0001; 36000-047; 71335-1208; 0143-9315; 33342-021
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erythema23.03.06.0010.011960%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000347%
Erythema of eyelid23.03.06.006; 06.04.04.0030.000173%Not Available
Extrapyramidal disorder17.01.02.007--
Extrasystoles02.03.02.0030.000347%Not Available
Extravasation08.01.03.0080.000953%Not Available
Eye disorder06.08.03.0010.000953%Not Available
Eye infection11.01.06.001; 06.04.05.007--
Eye inflammation06.04.05.0020.000433%Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.0020.001040%
Eye swelling06.08.03.0030.000520%Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.001647%Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.000173%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.002080%
Facial paralysis17.04.03.0080.000433%Not Available
Fatigue08.01.01.002--
Fear19.06.03.001--Not Available
Febrile neutropenia01.02.03.002; 08.05.02.004--
Feeling abnormal08.01.09.014--Not Available
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.0090.000867%Not Available
Feeling jittery08.01.09.016--Not Available
Femoral neck fracture15.08.03.002; 12.04.01.0020.000173%Not Available
Fixed drug eruption08.01.06.017; 23.03.05.006; 10.01.01.0220.000693%Not Available
Flatulence07.01.04.002--
Fluid overload02.05.04.004; 14.05.06.001--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.001473%
Foot fracture15.08.03.012; 12.04.01.012--Not Available
Foreign body aspiration22.02.07.008; 12.01.03.0010.000867%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 30 Pages